vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and UNITED FIRE GROUP INC (UFCS). Click either name above to swap in a different company.

BIOCRYST PHARMACEUTICALS INC is the larger business by last-quarter revenue ($406.6M vs $365.8M, roughly 1.1× UNITED FIRE GROUP INC). On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (209.1% vs 9.8%). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (109.4% CAGR vs 11.2%).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

The United Fruit Company was an American multinational corporation that traded in tropical fruit grown on Latin American plantations and sold in the United States and Europe. The company was formed in 1899 from the merger of the Boston Fruit Company with Minor C. Keith's banana-trading enterprises. It flourished in the early and mid-20th century, and it came to control vast territories and transportation networks in Central America, the Caribbean coast of Colombia, and the West Indies. Althou...

BCRX vs UFCS — Head-to-Head

Bigger by revenue
BCRX
BCRX
1.1× larger
BCRX
$406.6M
$365.8M
UFCS
Growing faster (revenue YoY)
BCRX
BCRX
+199.3% gap
BCRX
209.1%
9.8%
UFCS
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
109.4%
11.2%
UFCS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BCRX
BCRX
UFCS
UFCS
Revenue
$406.6M
$365.8M
Net Profit
$245.8M
Gross Margin
97.7%
Operating Margin
64.0%
13.2%
Net Margin
60.5%
Revenue YoY
209.1%
9.8%
Net Profit YoY
1017.5%
EPS (diluted)
$1.13
$1.45

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
UFCS
UFCS
Q4 25
$406.6M
$365.8M
Q3 25
$159.4M
$354.0M
Q2 25
$163.4M
$335.5M
Q1 25
$145.5M
$331.1M
Q4 24
$131.5M
$333.2M
Q3 24
$117.1M
$323.0M
Q2 24
$109.3M
$301.2M
Q1 24
$92.8M
$296.0M
Net Profit
BCRX
BCRX
UFCS
UFCS
Q4 25
$245.8M
Q3 25
$12.9M
$39.2M
Q2 25
$5.1M
$22.9M
Q1 25
$32.0K
$17.7M
Q4 24
$-26.8M
Q3 24
$-14.0M
$19.7M
Q2 24
$-12.7M
$-2.7M
Q1 24
$-35.4M
$13.5M
Gross Margin
BCRX
BCRX
UFCS
UFCS
Q4 25
97.7%
Q3 25
98.6%
Q2 25
98.3%
Q1 25
96.9%
Q4 24
95.4%
Q3 24
97.3%
Q2 24
98.4%
Q1 24
98.6%
Operating Margin
BCRX
BCRX
UFCS
UFCS
Q4 25
64.0%
13.2%
Q3 25
18.6%
13.7%
Q2 25
18.2%
8.7%
Q1 25
14.6%
6.6%
Q4 24
-3.4%
11.9%
Q3 24
6.6%
7.7%
Q2 24
8.0%
-1.3%
Q1 24
-15.6%
5.5%
Net Margin
BCRX
BCRX
UFCS
UFCS
Q4 25
60.5%
Q3 25
8.1%
11.1%
Q2 25
3.1%
6.8%
Q1 25
0.0%
5.3%
Q4 24
-20.4%
Q3 24
-12.0%
6.1%
Q2 24
-11.6%
-0.9%
Q1 24
-38.1%
4.6%
EPS (diluted)
BCRX
BCRX
UFCS
UFCS
Q4 25
$1.13
$1.45
Q3 25
$0.06
$1.49
Q2 25
$0.02
$0.87
Q1 25
$0.00
$0.67
Q4 24
$-0.13
$1.22
Q3 24
$-0.07
$0.76
Q2 24
$-0.06
$-0.11
Q1 24
$-0.17
$0.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
UFCS
UFCS
Cash + ST InvestmentsLiquidity on hand
$274.7M
$156.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$-119.2M
$941.2M
Total Assets
$514.2M
$3.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
UFCS
UFCS
Q4 25
$274.7M
$156.3M
Q3 25
$212.9M
$233.7M
Q2 25
$260.0M
$202.1M
Q1 25
$295.1M
$183.7M
Q4 24
$320.9M
$200.9M
Q3 24
$96.8M
$197.4M
Q2 24
$78.4M
$153.4M
Q1 24
$84.3M
$217.8M
Stockholders' Equity
BCRX
BCRX
UFCS
UFCS
Q4 25
$-119.2M
$941.2M
Q3 25
$-387.9M
$898.7M
Q2 25
$-421.6M
$845.7M
Q1 25
$-451.9M
$817.7M
Q4 24
$-475.9M
$781.5M
Q3 24
$-468.6M
$785.8M
Q2 24
$-475.6M
$726.6M
Q1 24
$-476.2M
$736.8M
Total Assets
BCRX
BCRX
UFCS
UFCS
Q4 25
$514.2M
$3.8B
Q3 25
$446.4M
$3.8B
Q2 25
$457.2M
$3.7B
Q1 25
$480.0M
$3.5B
Q4 24
$490.4M
$3.5B
Q3 24
$491.3M
$3.5B
Q2 24
$472.4M
$3.4B
Q1 24
$467.9M
$3.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCRX
BCRX
UFCS
UFCS
Operating Cash FlowLast quarter
$292.0M
$269.7M
Free Cash FlowOCF − Capex
$291.2M
FCF MarginFCF / Revenue
71.6%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
1.19×
TTM Free Cash FlowTrailing 4 quarters
$344.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCRX
BCRX
UFCS
UFCS
Q4 25
$292.0M
$269.7M
Q3 25
$41.6M
$60.8M
Q2 25
$41.3M
$53.4M
Q1 25
$-27.5M
$35.7M
Q4 24
$-5.2M
$340.3M
Q3 24
$8.2M
$56.5M
Q2 24
$-1.4M
$91.3M
Q1 24
$-53.7M
$36.2M
Free Cash Flow
BCRX
BCRX
UFCS
UFCS
Q4 25
$291.2M
Q3 25
$40.3M
Q2 25
$41.1M
Q1 25
$-27.7M
Q4 24
$-5.9M
Q3 24
$8.2M
Q2 24
$-1.5M
Q1 24
$-53.9M
FCF Margin
BCRX
BCRX
UFCS
UFCS
Q4 25
71.6%
Q3 25
25.3%
Q2 25
25.2%
Q1 25
-19.0%
Q4 24
-4.5%
Q3 24
7.0%
Q2 24
-1.4%
Q1 24
-58.1%
Capex Intensity
BCRX
BCRX
UFCS
UFCS
Q4 25
0.2%
Q3 25
0.8%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.1%
Q1 24
0.3%
Cash Conversion
BCRX
BCRX
UFCS
UFCS
Q4 25
1.19×
Q3 25
3.23×
1.55×
Q2 25
8.12×
2.33×
Q1 25
-859.91×
2.02×
Q4 24
Q3 24
2.86×
Q2 24
Q1 24
2.68×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons